At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks
In Brief
A Phase 3 clinical trial evaluating PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 555 participants across 31 sites in 2 countries.
Detailed Summary
The overall objective of this trial is to demonstrate clinically relevant superior antidepressant efficacy of the fixed dose combination PNB01 (low dose pipamperone and citalopram) over reference antidepressant treatment with citalopram alone, and a low dose of psychoactive pipamperone alone in patients with moderate to severe Major Depressive Disorder. This study was specifically designed to assess patient related outcome (PRO) parameters using an Interactive Voice Response System (IVRS) via telephone.
Study Details
Timeline
Interventions
oral once daily administration
oral once daily administration
oral once daily administration